Literature DB >> 27574989

Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats.

Camillo Benetti1, Lisa Flammini1, Valentina Vivo1, Paolo Colombo1, Gaia Colombo2, Lisa Elviri1, Carmelo Scarpignato3, Francesca Buttini1, Ruggero Bettini1, Elisabetta Barocelli1, Alessandra Rossi4.   

Abstract

The aim of this work was to study the esomeprazole activity on the control of gastric secretion after administration of a novel immediate release tablet. The ex vivo permeation of esomeprazole across porcine gastric mucosa from immediate release tablets, containing sodium carbonate or magnesium oxide as alkalinizing agents, was firstly assessed. Pharmacokinetics and pharmacodynamics studies in conscious rats following the administration of immediate release tablets with sodium carbonate, in comparison with delayed-release tablets having the same formula, were also conducted. The results showed an important effect of sodium carbonate and magnesium oxide on the drug release, on the ex vivo trans-mucosal transport and the stability in acid environment. In particular, the presence of sodium carbonate in esomeprazole tablet formulation provided the maximum increase of the drug in vitro transport across the mucosa. Then, the absorption and the antisecretory activity of this proton pump inhibitor orally administered in rats as immediate release tablets containing Na2CO3, was superior but not significantly different compared to delayed-release tablets having the same formula. In the adopted animal model, an activity of esomeprazole from immediate release alkaline formulation was seen also in presence of partial gastric absorption allowing inhibition of proton pumps reached via systemic circulation. This esomeprazole immediate release formulation could be used for the on-demand treatment of acid-related disorders such as gastro-esophageal reflux disease.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Esomeprazole; Ex vivo permeability; Immediate release; Pharmacodynamics; Pharmacokinetics; Rats

Mesh:

Substances:

Year:  2016        PMID: 27574989     DOI: 10.1016/j.jconrel.2016.08.032

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  4 in total

Review 1.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

2.  Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.

Authors:  Shan Jing; Yue Zhu; Wenfang Liu; Kexu Yang; Lili Hu; Dan Deng; Chunyan Lu; Yang Lin
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

3.  The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.

Authors:  Dasohm Kim; Min Soo Park; Byung Won Yoo; Taegon Hong; Shin Jung Park; Choon Ok Kim
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

4.  Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.

Authors:  Sungyeun Bae; Jihoon Kwon; Si-Beum Lee; In-Jin Jang; Kyung-Sang Yu; SeungHwan Lee
Journal:  Drug Des Devel Ther       Date:  2021-12-21       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.